 |
24 Diseases |  |
12 Trials |
|
12 Trials |  |
871 News |  |
| «12345678910111213» |
- || Briviact (brivaracetam) / UCB
Clinical, Journal, HEOR: Long-term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: An up to 11-year, open-label, follow-up trial. (Pubmed Central) - Oct 21, 2020
P2, P3
Brivaracetam reduced focal seizure frequency versus baseline. Efficacy improved with increasing exposure duration and remained stable through the 9-year cohort.
- |||| Briviact (brivaracetam) / UCB
A relatively new antiseizure medicine coming to Saudi Arabia and will be available soon You’re invited to attend this lecture to learn more about Brivaracetam and other new drugs For registration: https://t.co/mLUO1Z4vqM (Twitter) - Oct 14, 2020
- || Briviact (brivaracetam) / UCB
Clinical, Review, Journal: Antiepileptic Drug Selection According to Seizure Type in Adult Patients with Epilepsy. (Pubmed Central) - Oct 9, 2020
Currently there are 19 antiepileptic drugs approved by the Korean Food and Drug Administration, 18 of which (with the exclusion of brivaracetam) are covered by the National Health Insurance Service in Korea. We reviewed the selection of antiepileptic drugs according to the classification of epileptic seizures.
- | Briviact (brivaracetam) / UCB
Journal: Economic Value of Adjunctive Brivaracetam Treatment Strategy for Focal Onset Seizures in Finland. (Pubmed Central) - Oct 7, 2020
Thus, brivaracetam is likely a cost-effective and net beneficial alternative to perampanel for treatment of focal onset seizures. Plain language summary available for this article.
- | Briviact (brivaracetam) / UCB
Retrospective data, Journal: Effect of Brivaracetam on Efficacy and Tolerability in Patients With Brain Tumor-Related Epilepsy: A Retrospective Multicenter Study. (Pubmed Central) - Sep 27, 2020
Our results showed that BRV could be a new therapeutic option effective in reducing seizures in BTRE patients, taking into account the incidence of PAEs in this particular population. Future and larger prospective studies are needed.
- || Briviact (brivaracetam) / UCB
Clinical, Journal: Brivaracetam efficacy and safety in focal epilepsy. (Pubmed Central) - Sep 17, 2020
Behavioral adverse effects seemed less common that with LEV, and most patients switched to BRV after experiencing behavioral adverse effects on LEV reported improvement. Prior or anticipated intolerability to LEV is the strongest indication for BRV in clinical practice.
- | Journal: Timing use of novel anti-epileptic drugs: is earlier better? (Pubmed Central) - Sep 17, 2020
For this reason, the third-generation AEDs may be used earlier and earlier in epileptic patients. Further head-to-head comparisons are needed to determine the exact position of third-generation AEDs relative to conventional AEDs.
- || Briviact (brivaracetam) / UCB
Review, Journal: Intravenous Brivaracetam in the Treatment of Status Epilepticus: A Systematic Review. (Pubmed Central) - Sep 13, 2020
The available data suggested that brivaracetam can be a safe treatment option in patients with status epilepticus. The current evidence is however hampered by several confounding factors, and controlled studies are warranted to define the actual benefit of brivaracetam for the treatment of status epilepticus.
- | Briviact (brivaracetam) / UCB
Retrospective data, Journal: Brivaracetam substituting other antiepileptic treatments: Results of a retrospective study in German epilepsy centers. (Pubmed Central) - Sep 12, 2020
Incidences of behavioral AEs before (3-month baseline) and after brivaracetam initiation in patients who withdrew levetiracetam were 19.2% and 8.0%, respectively (5.0% and 7.7% in patients who withdrew other AEDs). Brivaracetam was effective and well-tolerated in patients who required a change in AED drug regimen and initiated adjunctive brivaracetam in German clinical practice.
- Briviact (brivaracetam) / UCB
[VIRTUAL] Time-limited Brivaracetam Treatment Lowers Incidence Of Chronic Seizures And Modifies Posttraumatic Epilepsy In Rats After Fluid Percussion Injury (Virtual Poster Hall) - Aug 28, 2020 - Abstract #NCS2020NCS_378;
- || Briviact (brivaracetam) / UCB
Clinical, Journal: Outcomes in three cases after brivaracetam treatment during pregnancy. (Pubmed Central) - Aug 27, 2020
Brivaracetam was effective and well-tolerated in patients who required a change in AED drug regimen and initiated adjunctive brivaracetam in German clinical practice. While the absence of major congenital malformations in these cases is encouraging, further data are needed to determine the safety of brivaracetam in pregnancy.
- | pregabalin / Generic mfg.
Review, Journal: Epilepsy and breastfeeding: from myth to reality (Pubmed Central) - Aug 23, 2020
Lamotrigine, phenobarbital, pregabalin, primidone, tiagabine, eslicarbazepine, brivaracetam, perampanel, zonisamide, lacosamide or the sporadic use of benzodiazepines in low doses are considered quite safe, with a low risk for breastfeeding. The other AEDs present a very low risk for breastfeeding.
- | Journal: Treatment of Refractory Convulsive Status Epilepticus: A Comprehensive Review by the American Epilepsy Society Treatments Committee. (Pubmed Central) - Aug 22, 2020
A structured literature search (MEDLINE, Embase, CENTRAL, CINAHL) was performed to identify original studies on the treatment of CRSE in children and adults using IV brivaracetam, ketamine, lacosamide, levetiracetam (LEV), midazolam (MDZ), pentobarbital (PTB; and thiopental), propofol (PRO), and valproic acid (VPA)...For the treatment of established convulsive SE (ie, not RSE), LEV, VPA, and fosphenytoin are likely equally effective, but whether this is also true for CRSE is unknown. Triple-masked, randomized controlled trials are needed to compare the effectiveness of parenteral anesthetizing and nonanesthetizing ASMs in the treatment of CRSE.
- || Briviact (brivaracetam) / UCB
Clinical, Journal: Safety and tolerability of adjunctive brivaracetam in children with focal seizures: Interim analysis of pooled data from two open-label trials. (Pubmed Central) - Aug 18, 2020
P2, P3
In this pooled analysis of two open-label trials including long-term data, adjunctive BRV was generally well tolerated in children aged 4 to <16 years with focal seizures. These findings supported approval of BRV as a new therapy option for children aged ≥4 years with focal seizures.
- || Briviact (brivaracetam) / UCB
Clinical, Journal: Adjunctive brivaracetam in focal and generalized epilepsies: A single-center open-label prospective study in patients with psychiatric comorbidities and intellectual disability. (Pubmed Central) - Aug 4, 2020
We demonstrated a higher incidence of treatment-emergent AEs leading to lower retention rates compared with previous studies across all patient groups. There were, however, no significant differences in tolerability between patients with preexisting psychiatric or behavioral comorbidities, or intellectual disability to those without.
- Briviact (brivaracetam) / UCB
[VIRTUAL] 3xTg Alzheimers disease mice are more susceptible to induced seizures. () - Aug 2, 2020 - Abstract #AAIC2020AAIC_1674;
The seizures of the 3xTg mice are more resistant to clinically used ASDs. The 6 Hz corneal kindling in mice is increasingly established as a model of epileptogenesis and an accessible model to assess seizure susceptibility and ASD effect in fully kindled AD mice.
- || Briviact (brivaracetam) / UCB
Clinical, Journal: Treatment with brivaracetam in children - The experience of a pediatric epilepsy center. (Pubmed Central) - Jul 29, 2020
Brivaracetam is an effective add-on treatment in focal, as well as generalized seizures in children, with negligible side effects, including children who failed previously on levetiracetam. Seizure exacerbation may occur, but it's reason is unclear.
- ||| brivaracetam / Generic mfg.
Trial completion: BASE: Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures (clinicaltrials.gov) - Jul 21, 2020
P=N/A, N=551, Completed, Sponsor: UCB Biopharma S.P.R.L.
Seizure exacerbation may occur, but it's reason is unclear. Active, not recruiting --> Completed
- ||| brivaracetam / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date: Brivaracetam: a Prospective and Multicentre Post-marketing Observational Study (clinicaltrials.gov) - Jul 20, 2020
P=N/A, N=200, Recruiting, Sponsor: Centre hospitalier de l'Universit
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Jun 2020 --> Dec 2021
- | padsevonil (UCB0942) / UCB
Preclinical, Journal: Pharmacological profile of the antiepileptic drug candidate padsevonil - characterization in rodent seizure and epilepsy models. (Pubmed Central) - Jul 16, 2020
Furthermore, in one rodent model, its efficacy extended beyond the combination of drugs interacting separately with SV2 or the benzodiazepine site. Padsevonil displayed a high therapeutic index, potentially translating into a favorable safety profile in humans; tolerance to antiseizure effects was not observed.
- | padsevonil (UCB0942) / UCB
Journal: Pharmacological profile of the novel antiepileptic drug candidate padsevonil - interactions with synaptic vesicle 2 proteins and the GABAA receptor. (Pubmed Central) - Jul 16, 2020
Results of in vitro and in vivo radioligand binding assays confirmed this target profile padsevonil displayed nanomolar affinity for the three synaptic vesicle 2 protein isoforms (SV2A, B and C) and micromolar affinity for the benzodiazepine binding site on GABA receptors. Furthermore, padsevonil showed higher affinity for, and slower binding kinetics at SV2A than the selective SV2A ligands, levetiracetam and brivaracetam.
- | Briviact (brivaracetam) / UCB
Journal: Development of an effective novel validated stability-indicating HPLC method for the resolution of brivaracetam stereoisomeric impurities. (Pubmed Central) - Jul 15, 2020
The enrichment of isomeric impurity, (R,R)-brivaracetam, was observed under basic stress conditions of brivaracetam and proposed a plausible mechanism to enhance that isomeric impurity. As well, a good separation among brivaracetam and its stereoisomeric impurity peaks was observed in the presence of degradation products and process-related impurities.
- || brivaracetam / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy (clinicaltrials.gov) - Jul 8, 2020
P2, N=50, Recruiting, Sponsor: UCB Biopharma S.P.R.L.
As well, a good separation among brivaracetam and its stereoisomeric impurity peaks was observed in the presence of degradation products and process-related impurities. Suspended --> Recruiting | Trial completion date: Apr 2020 --> Sep 2020 | Trial primary completion date: Apr 2020 --> Sep 2020
- || brivaracetam / Generic mfg.
Enrollment open: A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures (clinicaltrials.gov) - Jul 1, 2020
P2/3, N=42, Recruiting, Sponsor: UCB Biopharma S.P.R.L.
Suspended --> Recruiting | Trial completion date: Apr 2020 --> Sep 2020 | Trial primary completion date: Apr 2020 --> Sep 2020 Suspended --> Recruiting
- || pregabalin / Generic mfg., Briviact (brivaracetam) / UCB, carbamazepine / Generic mfg.
PK/PD data, Retrospective data, Journal: Pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with focal seizures: Pooled analysis of data from randomized clinical trials. (Pubmed Central) - Jun 28, 2020
P2, P3
In adults with focal seizures, adjunctive BRV treatment does not affect plasma concentrations of the evaluated AEDs but increases carbamazepine epoxide metabolite. Carbamazepine dose reduction should be considered if tolerability issues arise.
- | Briviact (brivaracetam) / UCB
Retrospective data, Journal: Relative performance of brivaracetam as adjunctive treatment of focal seizures in adults: a network meta-analysis. (Pubmed Central) - Jun 12, 2020
However, patient heterogeneity within trials and in clinical practice should be considered when interpreting these results. While NMAs are based on the best available evidence the authors suggest that, due to the inability of NMAs to capture unmeasured confounding factors and population heterogeneity, NMAs must not be the sole basis for comparative treatment recommendations.
- | Briviact (brivaracetam) / UCB
Preclinical, Journal: [EXPRESS] Brivaracetam attenuates pain behaviors in a murine model of neuropathic pain. (Pubmed Central) - Jun 4, 2020
SV2A may represent a novel target for neuropathic pain. BRV may warrant study in humans with neuropathic pain due to peripheral nerve injury.
- Briviact (brivaracetam) / UCB
[VIRTUAL] Multicenter Retrospective Study evaluating Brivaracetam in the treatment of epilepsies in clinical practice. (ePoster) - May 17, 2020 - Abstract #EAN2020EAN_3370;
- || pregabalin / Generic mfg., Trileptal (oxcarbazepine) / Novartis
Clinical, Journal: Therapeutic drug monitoring newer antiepileptic drugs: a randomised trial for dosage adjustment. (Pubmed Central) - May 13, 2020
Poor correlation between clinical effects and drug levels likely accounts for this finding. However, TDM is useful in several situations, such as pregnancy, as well as compliance issues.
- | brivaracetam / Generic mfg.
New P1/2 trial: Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury (clinicaltrials.gov) - May 6, 2020
P1/2, N=20, Not yet recruiting, Sponsor: University of Minnesota
- || Briviact (brivaracetam) / UCB
Clinical, Journal: A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers. (Pubmed Central) - Apr 29, 2020
P1
BRV achieves high SO more rapidly than LEV when intravenously administered at therapeutic doses. Thus, BRV may have utility in treating acute seizures; further clinical studies are needed for confirmation.
- |||| brivaracetam / Generic mfg.
Trial completion date, Trial primary completion date: Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy (clinicaltrials.gov) - Apr 24, 2020
P3, N=600, Enrolling by invitation, Sponsor: UCB Pharma SA
Thus, BRV may have utility in treating acute seizures; further clinical studies are needed for confirmation. Trial completion date: Jul 2022 --> Jun 2021 | Trial primary completion date: Jul 2022 --> Jun 2021
- | Afinitor (everolimus) / Novartis
Journal: New anti-epileptic drugs in Paediatrics (Pubmed Central) - Apr 23, 2020
These new molecules have been developed in order to provide a pharmaceutical profile and tolerance superior to the previously available drugs, and it is forecast that as their use increases, their true potential and profile will widen. Furthermore, for the first time in Paediatric Epileptology, the extrapolation of the efficacy data in adults have been used (together with specific safety and pharmacokinetic studies in the paediatric population), in order to speed up their approval for use in the child population.
- ||| brivaracetam / Generic mfg.
Trial suspension: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy (clinicaltrials.gov) - Apr 19, 2020
P2, N=50, Suspended, Sponsor: UCB Biopharma S.P.R.L.
Furthermore, for the first time in Paediatric Epileptology, the extrapolation of the efficacy data in adults have been used (together with specific safety and pharmacokinetic studies in the paediatric population), in order to speed up their approval for use in the child population. Recruiting --> Suspended
- ||| brivaracetam / Generic mfg.
Trial suspension: A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures (clinicaltrials.gov) - Apr 17, 2020
P2/3, N=42, Suspended, Sponsor: UCB Biopharma S.P.R.L.
Recruiting --> Suspended Recruiting --> Suspended
- || Briviact (brivaracetam) / UCB
Clinical, Journal: Use of intravenous brivaracetam in status epilepticus: A multicenter registry. (Pubmed Central) - Apr 16, 2020
BRV is useful for the treatment of SE, even when patients are already being treated with LEV. The response rate seems higher when it is administered earlier and at higher doses (>1.82 mg/kg).
- || carbamazepine / Generic mfg.
Retrospective data, Review, Journal: The medical treatment of epilepsy in the elderly: A systematic review and meta-analysis. (Pubmed Central) - Apr 15, 2020
There is some evidence for AED use in the elderly with epilepsy. More evidence is required, comparing newer AEDs to prior generations as well as examining the effects of determinants such as frailty, to guide clinicians when treating this rapidly growing patient population.
- | Briviact (brivaracetam) / UCB
Journal: Effects of cannabidiol on brivaracetam plasma levels. (Pubmed Central) - Apr 15, 2020
One possible mechanism contributing at least partially to increasing BRV level is the inhibition of CYP2C19 by cannabidiol. Further pharmacokinetic studies are required to understand other possible mechanisms of brivaracetam-cannabidiol interaction.
- | carbamazepine / Generic mfg.
Journal: Effects of antiepileptic drugs on cortical excitability in humans: A TMS-EMG and TMS-EEG study. (Pubmed Central) - Apr 10, 2020
Findings corroborate the view that the P25 represents axonal excitability of the corticospinal system, the N100 in the nonstimulated hemisphere propagated activity suppressed by inhibition of presynaptic neurotransmitter release, and the P180 late activity particularly sensitive to VGSC blockade. Pharmaco-physiological characterization of TEPs will facilitate utilization of TMS-EEG in neuropsychiatric disorders with altered excitability and/or network connectivity.
- Briviact (brivaracetam) / UCB
[VIRTUAL] evaluating Brivaracetam in the treatment of epilepsies in clinical practice. (Room: Screen B7) - Apr 9, 2020 - Abstract #EAN2020EAN_1927;
Pharmaco-physiological characterization of TEPs will facilitate utilization of TMS-EEG in neuropsychiatric disorders with altered excitability and/or network connectivity. Brivaracetam seems to be an effective, easy to use and safe antiepileptic drug in clinical setting
- Fycompa (perampanel) / Eisai, Briviact (brivaracetam) / UCB
[VIRTUAL] Comparing the effectiveness and tolerability of Perampanel and Brivaracetam: a preliminary retrospective, observational study based on real-world data (HoC Room) - Apr 9, 2020 - Abstract #EAN2020EAN_1574;
Moreover, we considered the effects of both drugs after distributing patients for age (≥60 y.o.), gender, and whether previously treated by Levetiracetam (LEV). This retrospective study observed comparable effectiveness and tolerability of PER and BRV as add-on treatments in patients affected with epilepsy, as well as when starting these drugs as first add-on treatments.
- Fycompa (perampanel) / Eisai, Briviact (brivaracetam) / UCB
[VIRTUAL] Epilepsy and women: reproduction (Room: Screen B7) - Apr 9, 2020 - Abstract #EAN2020EAN_1231;
New generation AEDs (perampanel, brivaracetam) allowed achieving remission at first and second polytherapy. The reported study was funded by RFFR according to the research project № 18-013-00222
- | Journal: Use of Newer Anticonvulsants for the Treatment of Status Epilepticus. (Pubmed Central) - Apr 4, 2020
One case report and two case series of stiripentol were found with reported efficacy between 60-100% in SRSE. Currently, there is insufficient evidence to support the use of these agents in this setting.
- sertraline / Generic mfg.
[VIRTUAL] Psychiatric symptoms associated with septo-optic dysplasia. (All Screens in Poster Area) - Feb 20, 2020 - Abstract #EPA2020EPA_1061;
Dysfunctional brain structures can cause hormonal, mood or behavior disorders. Clinical heterogeneity may difficult a therapeutic approach.
- | Fycompa (perampanel) / Eisai, Briviact (brivaracetam) / UCB
Journal: Neural Networks in Generalized Epilepsy and Novel Antiepileptic Drugs. (Pubmed Central) - Feb 16, 2020
In this treatment, perampanel can be combined with other antiepileptic drugs. Brivaracetam, which shows a high affinity for the synaptic vesicle 2A, exerted a good efficacy in the treatment of adult focal seizures and secondarily generalized tonic-clonic seizures.
- | lacosamide / Generic mfg., Fycompa (perampanel) / Eisai, Briviact (brivaracetam) / UCB
Review, Journal: Intractable Generalized Epilepsy: Therapeutic Approaches. (Pubmed Central) - Feb 9, 2020
Resective surgical options have demonstrated success in carefully selected patients despite generalized electrographic findings on electroencephalogram. The current literature reflects a widening range of clinical experience with newer anticonvulsant medications including cannabinoids, dietary therapies, surgical approaches, and neurostimulation devices for patients with intractable generalized epilepsy.
- || Briviact (brivaracetam) / UCB
Clinical, Journal: Effect of brivaracetam on the anger levels of epilepsy patients. A prospective open-labelled controlled study. (Pubmed Central) - Jan 25, 2020
This study shows that brivaracetam is not associated with an increased level of anger in patients with either focal or generalised epilepsies in the absence of psychiatric comorbidity. However, an improvement in anger levels is possibly influenced by a good seizure response.
- Concomitant Medication in Adolescent and Adult Individuals with Angelman Syndrome: Baseline Results from the Phase 2 STARS Study () - Jan 21, 2020 - Abstract #AAN2020AAN_1673;
Healthcare burden of participants in the STARS study was high with nearly all participants reporting surgeries, comorbidities and medication use. These results are consistent with recently published observational studies in individuals with AS that used the data from the AS Natural History Study (NHS).
- Briviact (brivaracetam) / UCB
Long-term Tolerability and Retention of Adjunctive Brivaracetam in Children With Primary Generalized or Mixed Seizure Types: Interim Subgroup Analysis of Pooled Data From two Open-label Trials () - Jan 21, 2020 - Abstract #AAN2020AAN_1231;
P2, P3
Two-year retention rate (approximately 50%) suggests potential treatment benefit in this pediatric population. Additional studies are needed.
- Briviact (brivaracetam) / UCB, carbamazepine / Generic mfg., Trileptal (oxcarbazepine) / Novartis
Real-world Study of Brivaracetam in the US: an Interim Analysis () - Jan 21, 2020 - Abstract #AAN2020AAN_1230;
Determine whether BRV retention is associated with lifetime levetiracetam (LEV), lamotrigine (LTG), oxcarbazepine (OXC), or carbamazepine (CBZ) failure. This interim analysis indicates that BRV retention (a measure of effectiveness) at 3 and 6 months is similar between patients that previously failed LEV, LTG, OXC, and CBZ.